← Back to Search

Monoclonal Antibodies

Trevogrumab + Garetosmab + Semaglutide for Obesity (COURAGE Trial)

Anniston, AL
Phase 2
Waitlist Available
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
You have been diagnosed with Nonalcoholic Steatohepatitis
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 75 weeks

Summary

This trial is testing two new drugs, trevogrumab and garetosmab, along with a drug called semaglutide (Wegovy®), in both healthy participants and

See full description
Who is the study for?
This trial is for adults aged 18-55 with a BMI of 18-32 (Part A), and those aged 18-80 with obesity, defined as a BMI over 30 (Part B). Participants should have tried to lose weight unsuccessfully before. It's not clear what excludes someone from joining.Check my eligibility
What is being tested?
The study tests trevogrumab alone or combined with garetosmab and semaglutide in two parts: Part A focuses on safety in healthy individuals; Part B examines effectiveness for weight loss in obese participants using various drug combinations.See study design
What are the potential side effects?
Potential side effects include reactions to the drugs such as allergies, possible development of antibodies against the drugs reducing their effectiveness, and other unspecified side effects that will be monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with Nonalcoholic Steatohepatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 75 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 75 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of treatment-emergent adverse events (TEAEs)
Secondary study objectives
Body weight reduction of ≥10%
Body weight reduction of ≥15%
Body weight reduction of ≥20%
+28 more

Trial Design

13Treatment groups
Experimental Treatment
Placebo Group
Group I: TrevogrumabExperimental Treatment1 Intervention
Part A Randomized 1:1
Group II: Arm D1Experimental Treatment3 Interventions
Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Group III: Arm D0Experimental Treatment4 Interventions
Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Group IV: Arm C1Experimental Treatment3 Interventions
Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Group V: Arm C0Experimental Treatment4 Interventions
Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Group VI: Arm B1Experimental Treatment3 Interventions
Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Group VII: Arm B0Experimental Treatment4 Interventions
Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Group VIII: Arm A1Experimental Treatment4 Interventions
Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1
Group IX: Arm A0Experimental Treatment3 Interventions
Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Group X: Arm 3Experimental Treatment3 Interventions
Part C Sema and SC moderate dose trevo Randomized 1:2:2
Group XI: Arm 2Experimental Treatment3 Interventions
Part C Sema and SC low dose trevo Randomized 1:2:2
Group XII: Arm 1Experimental Treatment2 Interventions
Part C Sema and SC placebo Randomized 1:2:2
Group XIII: PlaceboPlacebo Group1 Intervention
Part A Randomized 1:1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
2021
Completed Phase 4
~5160

Find a Location

Closest Location:Pinnacle Research Group· Anniston, AL

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
688 Previous Clinical Trials
947,338 Total Patients Enrolled
2 Trials studying Obesity
414 Patients Enrolled for Obesity
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
292 Previous Clinical Trials
255,734 Total Patients Enrolled
~434 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top